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Abstract Implantable peripheral neurostimulation was
introduced in 1969 as a potential treatment for certain
neuropathic pain syndromes, primarily involving the
limbs. While a few early studies included implants for
occipital neuralgia, serious interest in its potential as a
treatment for head pain came only after our 1999 report
of positive findings in a series of patients with occipital
neuralgia. Subsequent investigators confirmed these ini-
tial findings, and then extended the application to
patients with various primary headache disorders, in-
cluding migraine. While most found a therapeutic re-
sponse, the degree of that response varied significantly,
and analysis suggests that the issue of paresthesia con-
cordancy may be central, both in explaining the data, as
well as providing direction for future endeavors. There-
fore, while at present peripheral neurostimulation is gaining
increasing acceptance as a treatment for chronic headaches,
the precise clinical indications and procedures, as well as the
underlying neurophysiological mechanisms, are still being
worked out.
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Introduction
Migraine is a common disorder of the brain that exacts a
significant toll on the human condition. It afflicts at least
4 % of the population and dramatically impacts function in
terms of lost school and workdays [1]. The burden on patients
and society increases if the migraine becomes chronic, a cohort
in which over 50 % of patients feel their treatment to be
unsatisfactory [2]. Recognizing and responding to this clinical
challenge, over the past two decades professionals have devel-
oped various implantable neuromodulation techniques and eval-
uated these as potential treatment alternatives in this unfortunate
patient population. Here we review the significant aspects of
peripheral neuromodulation for headaches, including its genesis
and history, relevant clinical considerations and procedures, as
well as the work that has been done to elucidate possible
underlying mechanisms of action. Finally, considerations are
offered as to potential directions for future investigations.
History of Neuromodulation and Headaches
With the publication of their “Gate Control Theory” of pain
modulation in 1965, Wall and Melzack provided a conceptual
mechanistic foundation for considering direct electrical stimula-
tion of the spinal cord and peripheral nerves as a potential
treatment for chronic pain [3]. The prophetic nature of this work
was redeemed in 1969, when Shealy described positive
responses in patients implanted with spinal cord stimulators
(SCS), and Long implanted the first commercially available
peripheral nerve stimulators [4]. Thereafter, the bulk of clinical
investigations involved various applications of implantable SCS
for chronic back and extremity pain, and indeed, over the years
SCS has become widely accepted as a standard treatment meth-
odology for some patients with chronic back and extremity pain
unresponsive to more conservative measures [5].
This article is part of the Topical Collection on Chronic Daily
Headache
K. L. Reed (*)
Reed Migraine Centers, 11970 N Central Expy; Ste 510,
Dallas, TX 75243, USA
e-mail: klreed1@swbell.net
Curr Pain Headache Rep (2013) 17:305
DOI 10.1007/s11916-012-0305-8
Peripheral nerve stimulation (PNS) therapies for chronic
pain developed in parallel to SCS, albeit somewhat more
slowly. Over the 1970s and 1980s, Long, Nashold and
others documented favorable responses to open surgical
PNS implants in patients with various neuropathic pain
syndromes, most commonly of the limbs [6–11]. While
a few studies included isolated patients with occipital
neuralgia, serious attention to the potential of this meth-
odology as a treatment for head pain came only after
1999, when we presented implanted occipital nerve
stimulators (ONS) with percutaneously placed leads as a
novel therapeutic treatment for intractable occipital neuralgia
[12••]. Thereafter, interest in the technique spread rapidly,
and subsequent investigational work developed primarily
along two clinical avenues—PNS for cephalic neuralgias,
and PNS for primary headaches, the findings of which are
summarized in Tables 1 and 2.
PNS and Cephalic Neuralgias
Our report on ONS for occipital neuralgia was quickly fol-
lowed by a myriad of studies evaluating its application to
various neuropathic maladies afflicting the occipito-cervical
region, including occipital neuralgia, cervicogenic headache,
and other intractable C-2 mediated headaches [13–18, 19•,
20••, 21, 22•]. All groups reported consistent, remarkable
success rates on the order of 70–100 % (mean 89 %) (Table 1).
Over this same period, other investigators applied supraor-
bital nerve stimulation (SONS) to neuropathic pain perceived
over the frontal region and found similar results. In 2002,
Dunteman reported successful treatment of two patients with
ophthalmic post herpetic neuralgia with an implanted supra-
orbital nerve stimulator [23]. Succeeding Dunteman were a
host of investigations that applied PNS to supraorbital and
other painful trigeminal neuralgias, as reported on by Johnson
(2004), Slavin (2006), and Amin (2008), who all found long-
term 70–100% success rates [22•, 24, 25]. Yakolev extended
the indications in 2010 when he successfully treated a
patient with atypical facial pain with subcutaneous,
octipolar arrays over the mandible [26]. In 2012, Stidd
had two patients with trigeminal neuralgia respond well
to combined SONS and infraorbital nerve stimulation
(IONS) [27]. Evaluating these studies as a whole, we
find virtually the same success rates of 70–100 %
(mean 88 %) as we do with ONS and occipital pain.
Therefore, on the one hand, it’s interesting that the
reported response rates from the groups treating facial pain
with peripheral trigeminal stimulators are virtually identical
to the corresponding rates reported by those treating occip-
ital pain in the same manner (70–100 % success rates).
However, this should not be surprising, as it is in line with,
and essentially an extension of, the well-documented effec-
tiveness of implantable neurostimulators for analogous
painful neuropathies over the torso and the limbs. Indeed
both groups, neurostimulation is being applied to the same
underlying problem of neuropathic pain, just over different
neural distributions.
PNS and Primary Headaches
Occipital Neurostimulation and Headaches
The initial applications of PNS to cephalic pain continued in
line with the historical standard of neuropathic pain until
2003, when Dodick described a positive response to ONS in
a patient with cluster headaches, and Popeney found similar
results in a series of patients with transformed migraine
[20••, 28••]. These were the first reports on the use of PNS
for primary headaches, i.e., disorder of the brains, as op-
posed to a peripheral neuropathic pain, and they generated
wide interest in the potential of this methodology. As such,
the succeeding years witnessed a series of increasingly
sophisticated studies evaluating the responsiveness of pri-
mary headaches to ONS, with the corpus of work primarily
focused on cluster and chronic migraine headaches
[Table 2].
With respect to cluster headaches: following Dodick’s
2003 report on ONS, most of the clinical work was
published by seven different teams, who on average
reported a 62 % response rate, which was notably lower
than those rates seen when neurostimulation was applied
directly to the area of pain, e.g. the over 90% rates found with
PNS for occipital and various trigeminal neuralgias [29–38].
Arguably the most interest with respect to ONS and
primary headaches has centered around migraine. Begin-
ning in 2003, an initial series of relatively small studies
documented positive results [19•, 35, 38, 39], and ulti-
mately, each of three primary manufacturers undertook
large, multicenter, randomized, double-blinded, prospec-
tive studies evaluating the responsiveness of chronic
migraine to ONS. These included Boston Scientific’s
PRISM study (125 pts), St. Jude (105 implants; 52
controls), and Medtronic’s ONSTIM study (33 implants,
34 controls) [40•, 41••, 42••]. Using the historical stand-
ards for a positive response of over 50 % improvement
in either pain level or frequency, both the Boston and
St. Jude studies found no evidence for a significant
positive therapeutic result. St. Jude did note, however,
significant reductions of the VAS and HA days/mo at
approximately the 30 % level and that overall 52 % of
patients were satisfied at 12 weeks [41••]. Indeed,
Medtronic was the only to find a significant result in a primary
variable, as they reported a 39 % response rate at 3 months
(vs. < 6 % of controls; p<0.05) [42••]. Now, even this 39 %
rate needs be qualified, as a 30 % improvement in pain was
used to define a responder, rather than the standard 50 %.
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This is very important, as the clear clinical standard used to
define a positive response to a trial stimulator is over 50 %
improvement. Thus, of the three largest, double-blinded,
prospective studies that have been performed to date on
ONS and migraine, two found no significant support for an
adequate therapeutic effect, and the other found only a very
qualified 39 % success rate.
Supraorbital Neurostimulation for Headaches
In 2009, Narouze published the first successful applica-
tion of supraorbital nerve stimulation for cluster head-
aches, using NS implant protocols similar to those
applying ONS to cluster headaches [43•]. In 2012, Vais-
man fortified the validity of this technique, when he found
Table 1 Summary of patients treated with concordant neurostimulation
Report Dx No Perm Resp Rate Notes
Occipital Neuropathic Pain Treated with ONS Alone
Weiner, Reed [12••] ON 13 80 % 80 % had good to excellent relief
Rodrigo-Royo [21] ON 4 100 % 97 % avg decrease in VAS
Kapural [16] CEH 6 100 % 70 % avg decrease in VAS
Slavin [63] ON 10 70 % All had excellent pain relief at 6 mo
Johnstone [15] ON 7 71 % 73 % avg decrease in VAS
Melvin [17] ON 11 100 % 73 % rated relief as good to excellent
Shaldi [64] ON 8 88 % 71 % avg decrease VAS
Magown [65] ON 7 100 % 6 had 75–100 % improvement
Vadivelu [66] AC 15 87 % All had over 50 % improvement
Pameliere [19•] NC 8 100 % 80 % avg relief
Oh [15] ON 10 100 % All had 90–100 % relief
89 % avg
Trigeminal Neuropathic Pain Treated with Trigeminal Stim Alone
Dunteman [23] PHN 1 100 % SON
Johnson, Burchiel [25] TNP 10 70 % I SON; 2 ION
Slavin [22•] TNP 7 82 % 4 SON; 3 ION
Amin [24] SON 10 100 % SON
Yakolev [26] AFP 2 100 % Subcu octrodes over mandible
Stidd [27] TNP 3 100 % 1 SON; 2 SON-ION
88 % avg
Occipitally-Focused Migraine Headaches Treated with ONS Alone
Popeney [20••] TM 25 100 % 100 % responded
Oh [18] TM 10 90 % 90 % had >75 % improvement at 3–6 mo
Matharu [54••] CM 8 100 % 100 % had good to excellent relief
98 % avg
Frontal (Cluster) Headaches Treated with Trigeminal Stim Alone
Narouze [43•] Cl 1 100 % SON stim
Vaisman [44•] Cl 5 100 % SON stim
Simopoulos [67] CM 1 100 % ATN stim
100 % avg
Hemicephalic/global (Chronic Migraine Headaches) Treated with Combined Stim
Reed [45••] CM 7 100 % ON-SON stim
Desphande [46•] CM 1 100 % ON-ATN stim
Mammis [47•] Cl 1 100 % ON-SON-ION stim
Reed [54••] CM 44 87 % ON-SON stim
89 % avg
Summary: 93 % average response rate for all studies
ON occipital neuralgia; TM transformed migraine; CEH cervicogenic headaches; Dx diagnosis; IC2H Intractable C-2 Headaches; AC Arnold-
Chiari; CM chronic migraine; ATN Auriculotemporal Nerve; ION infraorbital nerve; SON supraorbital nerve
Unless otherwise specified, all success rates indicate >50 % improvement in VAS or HA frequency
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therapeutic responses to SONS in a series of five patients with
cluster headaches [44•].
Combined Occipital and Supraorbital Neurostimulation
for Headaches
Based on several convergent lines of consideration (see
below), in 2006 we hypothesized that using combined
ONS and SONS may be beneficial in some patients suffer-
ing from chronic migraine, where the pain is perceived in
hemicephalic or global extent (and therefore involving both
the trigeminal and occipital neural systems), and in 2009,
we reported on strongly positive responses in a series of
seven patients so treated. All were quite debilitated due to
daily incapacitating migraine, and all responded, with six
describing near complete resolution of the headaches (over
90 % improvement). Notably, one patient’s associated hemi-
plegia resolved as well [45••]. In 2011, Deshpande and
Mamis presented independent case studies on similar com-
bined approaches in patients with hemicrania continua (ON-
bilateral temple leads) and cluster headaches (ON-SON-
ION leads), respectively [46•, 47•]. Also in 2011, Linder
was the first to report on combined ON-SONS in adolescent
patients, finding therapeutic responses in 11 teenagers [48•].
In 2012, Datta first described the successful employment of
combined ON-SONS in a patient with severe migraine who
was post surgical decompression of the occipital nerves
[49•]. Finally, in 2011 while compiling outcome data on a
larger clinical database, our group presented in abstract
positive results in a series of 44 patients treated with the
same combined ON-SONS system [50•].
Historical Data Analysis and Issue of Concordancy
Paresthesia Concordancy
When implanting neurostimulator leads, the clinical stan-
dard has always been to seek a concordant paresthesia; that
is, to effort a neurostimulator induced paresthesia that, as
best as possible, covers the anatomic region of perceived
pain, which is the clinical indicator that the correct portion
of the nervous system is being stimulated [5]. For example,
when implanting a SCS in a patient with low back and right
leg pain, the technical goal is to place the leads in such a
manner as to have the paresthesia perceived over the same
regions of the low back and right leg. Indeed, the current
standard during all neurostimulator implants is to test the
system “on the table” by arousing the patient enough to
report the paresthesia location, whereby the surgeon adjusts
the lead tips to optimize that coverage. In fact, we are not
aware of any reports prior to 2003 where a stimulator was
Table 2 Summary of patients treated with non-concordant neurostimulation
Report Dx No Perm Resp Rate Notes
Cluster Treated with ONS Alone
Dodick [28••] Cl 1 100 % HA free after 12 mo
Burns [68, 69] Cl, HC 20 45 % 9 of 20 had >50 % imp
Magis [32] Cl 14 85 % 80 % had >90 % imp
Trentman [38] Cl 5 60 % 3 had fair to exc resp
Schwedt [35] Cl 8 60 % 60 % had >50 % imp
de Quintana [29] Cl 4 100 % All had >50 % imp
Fontaine [30] Cl 13 77 % 77 % had >50 % imp
Mueller [34] Cl 10 40 % All had >50 % imp in freq/sev
62 % avg
Chronic Migraine Headaches Treated with ONS Alone
Saper (Medtronic) [42••] CM 51 39 % 39 % had>30 % VAS imp
Silberstein (St. Jude) [41••] CM 105 35 % 35 % had>30 % VAS imp
Lipton (Boston Sc) [40•] CM 132 ? Statistical results not significant
Pameliere [19•] MWA 8 63 % 47 % average relief
Serra [39] CM 29 100 % MIDAS, SF36, meds all stat sig
48 % avg
Summary: 48 % average response rate (>50 % VAS imp) for all chronic migraine studies
37 % average response rate (>30 % VAS imp) for the “benchmark” Medtronic and St. Jude studies
Cl cluster; CM chronic migraine; HC hemicranias continua; MWA migraine without aura
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intentionally placed in a manner that did not seek a concor-
dant paresthesia. Even reports of neurostimulators in
patients with cardiac or abdominal visceral pain still have
the paresthesia localized to the appropriate thoracic or ab-
dominal dermatomes, respectively [51–53].
In patients with occipital neuralgia, or other headaches
that are focused over the occiput, ONS produces a clear
concordant paresthesia; to wit, the patient perceives the
paresthesia over the C1-2-3 distribution, which is the same
area where they feel the pain. The same holds true for
patients with neuropathic pain centered over the supraorbital
region that is treated by a supraorbital stimulator. Thus, all
of the studies related to treating occipital neuralgia with
ONS and the various localized trigeminal neuralgias with
SONS/IONS should be understood from the standpoint that
they are all simply following the historical standard of
concordant paresthesia. Indeed, as noted, their relative high
reported success rates of 70–100 % (avg. 89 %) are very
much in line with analogous studies involving concordant
paresthesias for neuropathic pain over the torso and limbs.
While possibly less obvious at first, the issue of pares-
thesia concordancy holds for some patients with migraine as
well. Both Popeney and Oh reported a subset of patients
with transformed migraine whose pain was primarily per-
ceived over the occiput [18, 20••]. Further, the reports on
ONS for chronic migraine by some of the studies, including
the Matharu, Schwedt and Trentman reports, explicitly not-
ed that most, if not all, of their patients had pain that was
prominent over the occipital region [35, 38, 54••]. Thus,
while all of these groups were evaluating migraine respon-
siveness to ONS, the patients so studied had pain primarily
focused over the occiput, and thus followed the historical
standard of a concordant paresthesia.
Most migraine headaches, however, are experienced over
the frontotemporal regions, and in these cases, ONS produ-
ces a non-concordant occipital paresthesia. With that in
mind, we believe that Dodick’s 2003 report on the use of
ONS for cluster headaches was a true watershed event, as it
was the first report in the history of neurostimulation and
pain to document the successful treatment of a patient in
pain with a non-concordant paresthesia. As it was unprece-
dented, it presented a challenge to understand how stimu-
lating the occipital nerves could ease pain over the distant
trigeminal nerves. Now, its unprecedented nature notwith-
standing, the extensive series of reports succeeding to
Dodick’s convincingly demonstrated that ONS did ease
migraine pain in some patients. On the other hand, the
accumulated database is also persuasive that the associated
response rates consistently fall below those groups treated
with a concordant paresthesia, e.g., occipital neuralgia trea-
ted with an occipital stimulation. As summarized in the
tables, whereas over 90 % of patients respond to NS systems
producing a concordant paresthesia, less than 40 % of
patients with chronic migraine will do so (considering the
benchmark double blinded studies).
Clinical Outcome Studies Analysis
The results of the significant studies on PNS and headaches
are summarized in the tables, which divide the patient treat-
ment groups into two: those implanted with systems that
produce a concordant paresthesia, e.g., ONS for occipital
neuralgia (Table 1), and those that produce a non-concordant
paresthesia, e.g., occipital stimulation for the pain of migraine
headaches perceived over the trigeminal fields (Table 2). Con-
trasting the results from the “concordant” group against those
of the “non-concordant” group reveals a striking difference in
the response rates, and one that pivots on the single variable of
paresthesia concordancy.
All five individual “concordant paresthesia” groups of
Table 1 reported very high and consistent response rates
(88 %, 89 %, 89 %, 98 % and 100 %, respectively) for an
overall response rate of 93 %. These results stand in sharp
contrast to those found in Table 2, which are those of the
groups studying implants that produce non-concordant par-
esthesias, which overall found less than a 40 % response
rate. Close scrutiny of the results of the benchmark Med-
tronic, Boston Scientific and St. Jude ONS studies suggests
that they all actually confirmed minimal to no response of
patients with chronic migraine to ONS. From that respect,
not only did both the St. Jude and Boston studies fail to
show a significant therapeutic response, Medtronic’s report
of a 39 % rate still did not meet the historical, clinical
standard of only counting patients with 50 % or more
improvement as responders.
It is this dramatic difference in the observed success rates
that provides such compelling support for the central impor-
tance of paresthesia concordancy.
Considerations on Mechanisms of Action
Questions arise as to how to best understand why ONS may
be less effective for migraine headaches than for occipitally
focused headaches; or alternatively, why combined stimula-
tion of both the occipital and the trigeminal branches may
achieve improved results for patients experiencing migraine
pain in either a hemicephalic or global distribution. These
questions should first be considered from the context of our
current understanding of the related functional neuroanato-
my, where interest has thus far largely centered on the
trigeminocervical complex (TCC) and potentially related
higher central nervous system (CNS) centers. Though the
data remains quite limited, it does provide some insights.
The TCC is formed by the caudal trigeminal nucleus and
portions of the upper three cervical dorsal horns.
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Nociceptive afferents from both the trigeminal nerve and the
occipital nerves (C1-2-3) partially converge on the same
second order neurons in the TCC, and thus to a final com-
mon pathway to higher centers for cephalic nociception and
modulation [55••, 56–58]. Bartsch and Goadsby’s meticu-
lous animal studies convincingly demonstrated both this
discrete convergence, as well as subsequent sensitization
of second-order TCC neurons following a sensory barrage,
findings that likely underlie the clinical observation of
referred pain seen with primary headaches [55••, 56]. In
2003, Popeney suggested that the TCC may be the neuro-
anatomical substrate underlying the clinical issue of pares-
thesia concordancy [20••].
There is also early but convincing evidence for the in-
volvement of higher CNS centers with neuromodulation.
Utilizing positron-emission tomography (PET scans), in
2003 Matharu documented responsiveness of some of these
higher centers to ONS. Paresthesia-correlated activation was
observed in the cuneus, pulvinar and anterior cingulate
cortex. Activation of the rostral dorsal pons demonstrated
a coverable response with pain scores and may be particu-
larly important in the genesis of chronic migraine [54••].
More recently, Magis documented similar PET scan findings
in patients with chronic cluster headaches [59].
One potential mechanism accounting for the responsive-
ness of frontal pain to a distant occipital paresthesia relates
to the experimentally confirmed observation that chronic
occipital pain may ultimately refer to the frontal regions,
and thus globalize [57, 58, 60, 61]. This implies that there is
a subset of patients with holocephalic headaches, whose
pain originated in the occipital region and only over time
globalized, thus explaining therapeutic responses to treat-
ments aimed at the occiput, the actual source of the problem.
In 1992, Anthony found that 48 % of patients with idiopath-
ic migraine headaches, and thus a frontal pain component,
responded to occipital nerve blocks and concluded that the
frontal component of the pain was referred [62]. Thus,
experimental evidence of referred occipital pain, combined
with the proposed possible substrate at the TCC, provides a
conceptual framework for a potential mechanism in some
patients with frontotemporal migraine pain to therapeutic
occipital measures, in the sense that these measures are
indeed focused on the actual source of the referred pain.
Clinical Approach
General
The typical patient being considered for a neurostimulator
implant has debilitating, chronic headaches and has been
under the care of an experienced headache specialist for
months or years. Commonly, the headaches were under good
control for a period, but ultimately became chronic and refrac-
tory to all reasonable measures, at which point the patient
becomes a candidate for trial neurostimulation. Following a
successful trial, the permanent unit (10-year battery life span)
is implanted. Postoperatively, most all patients report virtually
immediate relief from their headaches, and ultimately marked
reductions in medication requirements; improvement in their
overall sense of well-being, and associated marked increases
in their and energy and activity levels. The system is easily
maintained, and patients find that they are able to return to
family life, work and social interactions.
Candidacy
In general, a patient is considered a candidate for evaluation for
a PNS if they have severe, chronic headaches that have failed to
respond to more conservative measures. While there are no
strict criteria for candidacy, reasonable guidelines include:
& Chronic, debilitating headaches
& Failed extended course (> 3–6 mo) of more conservative
management
& Passed psychological prescreening
& Either on no, or minimal and stable, doses of narcotics
Issues that generally do affect candidacy include:
& Headache diagnosis—PNS has been studied and found
effective in various types of headaches, including mi-
graine, cluster, hemicranias continua, chronic daily
headache, transformed migraine, tension type head-
aches, occipital neuralgia, post-traumatic headaches
and cervicogenic headaches, amongst others.
& Gender
& Age—our implanted group’s ages range from 14 to 72
and include 25 adolescents
Trial Stimulation
The specific techniques involved in placement of both the
trial and permanent units have been well described in the
literature and will not be reviewed here.
The trial stimulator is percutaneously implanted in the
outpatient setting. Upon recovery, the patient is instructed in
the operation of the programmable battery and discharged.
During the next five days, the patient is advised to test the
unit under all practical circumstances, including work, play,
travel, etc. The patient returns typically five days later for
removal of the unit and evaluation of the results.
A trial PNS is very reliable in predicting the results of the
permanent unit. While false-positives may occur, the fact is
that less than 2 % of patients ever return after a permanent
unit, complaining of loss of efficacy and requesting remov-
al. The underlying reason for this reliability largely relates to
305, Page 6 of 10 Curr Pain Headache Rep (2013) 17:305
the typically dramatic nature of the response—one way or
the other. That is, most patients typically report either a
markedly positive response, often describing near complete
resolution of the headaches, or they tend to virtually not
respond at all. While of course possible, it is in practice
rather unusual for a patient to be “unsure” as to whether or
not the trial stimulator effectively eased their pain. From a
different viewpoint, the trial period is showing the patient
what they can expect with a permanent unit. In this sense,
the trial is quite truly a “test drive” of a neurostimulator,
such that the patient knows before the permanent implant
exactly what they can expect with the unit. It is one of the
few times in medicine that there is indeed a test to see how
well a patient will do with a specific surgical treatment that
is available before the patient has the surgery.
At the conclusion of the trial period, the patient is seen in
the office where the unit leads are removed and the response
evaluated. While the minimum requirement for a positive
response is over 50 % improvement, the majority of res-
ponders describe 80 % to over 95 % improvement. For
patients finding a positive response and desirous of proceed-
ing, the permanent implant is scheduled.
Permanent Implant
A permanent stimulator involves the placement of an implant-
able pulse generator (IPG) and from 1 to 4 leads based upon
the patients headache, pain location and trial results (Fig. 1).
This is a relatively straightforward surgical procedure that is
accomplished either as an outpatient or with an overnight stay.
Recovery
As all incisions are relatively superficial, recovery and re-
sumption of activity is fairly rapid. Most patients are able to
resume normal activities, including travel, within 2–3 days.
Those who have sedentary work positions may return to
work within a week. Patients should avoid extreme physical
activity for the full recovery period of 6 weeks, at which
point all restrictions are removed.
Life with a Neurostimulator
Following the 6-week recovery period, the most remarkable
thing about managing a stimulator is how simple it is. The only
maintenance required involves the simple process of twice
weekly recharging their unit, which involves simply sitting
next to a portable recharging unit (RF couple) for an hour.
Following the initial 6-week recovery period, we often have
patients return to the office on an as needed basis only. Thus,
from the patient’s standpoint, most everything improves.
& Medication requirements—almost invariably meds mark-
edly decrease, corresponding to the improvement pain.
Over 30 % of patients no longer require any routine meds,
and most of the rest see marked reductions.
& Psychological status—typically marked improvement in
any related issues such as anxiety or depression, with a
concomitant improvement in sense of well-being
& Activity level
– No longer frequenting medical facilities or having to
stay in due a headache, patients are able to fully return
to normal activities of daily living, including interact-
ing with the family and enjoying social occasions.
– Further, we impose absolutely no activity restrictions.
We have patients that returned to, or became involved
with, various strenuous physical activities, including
all forms of exercise, gymnastics, horseback riding,
martial arts, baseball, and skiing, without problems.
Risks and Adverse Events
PNS for head pain is generally considered to be very safe over
the long term. In practical terms, complications are uncommon
Fig. 1 Schematic depiction of a subcutaneously implanted combined
occipital and supraorbital nerve stimulator. A standard implant is
presented with the battery (IPG) located in the upper, outer gluteal
region. a. From the IPG, four leads are passed subcutaneously such that
two of the active terminal arrays are positioned over the greater
occipital nerves. b. Two leads are passed over the ear to final subcu-
taneous positions of the terminal arrays over the supraorbital nerves.
Standard strain-relief loops are depicted over the ear and at the IPG
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and are largely limited to a small (3–6 %) risk of infection.
However, given the subcutaneous location of the systems, any
infections are superficial and invariably respond to antibiotics,
and usually with temporary explant of the device. We are
unaware of any reports in these patient groups of serious
complications that have resulted in long-term morbidity.
Other clinical considerations here relate to technical issues
due the nature of the implant, and include lead migration or
fracture and IPG malfunction, and though frustrating, are
easily remedied with a short outpatient procedure.
Conclusion
Following our initial introduction of ONS for occipital neu-
ralgia in 1999, a plenitude of clinical reports both confirmed
our initial findings and also initially extended the methodolo-
gy to the frontal region and the trigeminal neuralgias, and then
ultimately to primary headaches, particularly clusters and
chronic migraine. Indeed, virtually all extant reports find a
therapeutic response to PNS with minimal downside, and
when considered together with the basic science research,
provide a coherent, consistent and substantive basis for PNS
treatment for the cephalic neuropathic pain disorders, as well
as for primary headaches. While there are many clinical and
foundational issues to address going forward, the database
supports an optimistic vision for the future of implanted
peripheral nerve stimulation and head pain. In considering
that future, we again emphasize the compelling evidence that
supports moving towards considering paresthesia concord-
ancy, both when planning system implants for individual
patients, as well as for future research protocols.
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